Literature DB >> 16005121

Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.

Robert E Johnston1, Philip R Johnson, Mary J Connell, David C Montefiori, Ande West, Martha L Collier, Chad Cecil, Ronald Swanstrom, Jeffrey A Frelinger, Nancy L Davis.   

Abstract

VEE replicon particles (VRP), non-propagating vaccine vectors derived from Venezuelan equine encephalitis virus (VEE), were engineered to express immunogens from the cloned isolate SIVsmH-4, combined in a vaccine cocktail and inoculated subcutaneously to immunize rhesus macaques. The virulent, uncloned challenge stock, SIVsmE660, represented a type of heterologous challenge and the intrarectal challenge modeled infection across a mucosal surface. Prechallenge neutralizing antibodies against SIVsmH-4 were induced in all vaccinates, and a prechallenge cellular immune response could be detected in one of six. Post-challenge, virus loads were reduced at the peak, at set point and at termination (41 weeks post-challenge), although these differences did not reach statistical significance. Significantly elevated levels of CD4+ T cells were observed post-challenge. A strong correlation was noted between a net increase in CD4+ T cell count and lowered virus load at set point.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005121     DOI: 10.1016/j.vaccine.2005.05.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers.

Authors:  Konstantin Virnik; Yisheng Ni; Ira Berkower
Journal:  Vaccine       Date:  2012-07-06       Impact factor: 3.641

2.  Mucosal and systemic adjuvant activity of alphavirus replicon particles.

Authors:  Joseph M Thompson; Alan C Whitmore; Jennifer L Konopka; Martha L Collier; Erin M B Richmond; Nancy L Davis; Herman F Staats; Robert E Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

3.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 4.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

5.  Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.

Authors:  Joseph M Thompson; Alan C Whitmore; Herman F Staats; Robert E Johnston
Journal:  Vaccine       Date:  2008-06-09       Impact factor: 3.641

6.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

7.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

8.  Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques.

Authors:  Myrna C Bonaldo; Mauricio A Martins; Richard Rudersdorf; Philip A Mudd; Jonah B Sacha; Shari M Piaskowski; Patrícia C Costa Neves; Marlon G Veloso de Santana; Lara Vojnov; Saverio Capuano; Eva G Rakasz; Nancy A Wilson; John Fulkerson; Jerald C Sadoff; David I Watkins; Ricardo Galler
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species.

Authors:  Andrea Kirmaier; Fan Wu; Ruchi M Newman; Laura R Hall; Jennifer S Morgan; Shelby O'Connor; Preston A Marx; Mareike Meythaler; Simoy Goldstein; Alicia Buckler-White; Amitinder Kaur; Vanessa M Hirsch; Welkin E Johnson
Journal:  PLoS Biol       Date:  2010-08-24       Impact factor: 8.029

10.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.